Biological Evaluation of Arylsemicarbazone Derivatives as Potential Anticancer Agents.
Nascimento da Cruz AC, Brondani DJ, I Talo de Santana T, Oliveira da Silva L, da Oliveira Borba EF, de Faria AR, Ferreira Cavalcanti de Albuquerque J, Piessard S, Matos Ximenes R, Baratte B, Bach S, Ruchaud S, Bezerra Mendonça Junior FJ, Bazin MA, Montenegro Rabello M, Hernandes MZ, Marchand P, Gonçalves da Silva T.
Nascimento da Cruz AC, et al. Among authors: bazin ma.
Pharmaceuticals (Basel). 2019 Nov 17;12(4):169. doi: 10.3390/ph12040169.
Pharmaceuticals (Basel). 2019.
PMID: 31744203
Free PMC article.